Full-Time

Senior Manager

Regulatory Planning

Posted on 11/11/2024

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS cancers

Biotechnology
Healthcare

Compensation Overview

$135k - $175kAnnually

Senior

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Risk & Compliance
Legal & Compliance
Requirements
  • 5+ years of Regulatory Planning or equivalent experience.
  • Proficient in Smartsheet and OnePager.
  • Understanding of eCTD and relevant submission formatting, transmittal and archiving regulations and guidelines.
  • Knowledge of ex-US eCTD submissions and submissions processes.
  • Outstanding interpersonal and communication (written and verbal) skills: able to work with multiple groups of people at one time, remaining calm, professional, diplomatic and positive.
Responsibilities
  • Understand regulatory submissions and activities.
  • Ensure effective communication of regulatory submissions and activities globally, to help ensure timely and accurate dissemination of regulatory workstreams.
  • Identify, establish, and manage databases/information sources to track key deliverables and information.
  • Provide scenario and visualization support to drive proactive planning and rapid and informed decision making.
  • Develop, execute, and maintain submission delivery plans, submission content plans, and proactively provide status updates.
  • Identify regulatory bottlenecks or resource constraints based on Planning outputs.
  • Demonstrate strategic mindset to support comprehensive strategies that align with organizational goals and regulatory requirements for efficient execution.
  • Identifies opportunities for process improvements and create best practices.
  • Manages the input, upkeep, and revisions of project plans for assigned projects, highlighting any unforeseen changes in resource requirements.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, which target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to concentrate their research and development efforts in this niche area. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

36%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for research and development.
  • Increased interest in targeted therapies boosts investment and partnership opportunities.
  • Shift towards personalized medicine aligns with their focus on genetic mutations.

What critics are saying

  • Integration challenges with EQRx could disrupt operations and delay timelines.
  • EQRx's pricing model may conflict with Revolution Medicines' market strategies.
  • $600M public stock offering may dilute existing shareholder value.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive licensing with the University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE